BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Image Results

Loading...
Loading...

RAPTIVA Pages on BioPortfolio:

Biotechnology News RAPTIVA Search
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory.
http://www.bioportfolio.co.uk/RAPTIVA-news.htm...

BioPortfolio - Raptiva
Raptiva - BioPortfolio - Indepth. ... Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
...
http://www.bioportfolio.com/indepth/Raptiva.html...

BioPortfolio.com - BioWeb OMNITROPE SOMATROPIN RECOMBINANT isrupt ...
Home Contact Us Site Index Search [ Products -- Nutropin ] Products Home ONCOLOGY Avastin Herceptin Rituxan Tarceva IMMUNOLOGY Raptiva Xolair VASCULAR
...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?DB=se...

BioPortfolio News: BioTrends Research Group, Inc. - Raptiva ...
BioTrends Research Group, Inc. - Raptiva Withdrawal Offers Upside for... - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/news/Raptiva_Withdrawal_Offers_U...

BioPortfolio.com - BioWeb AVASTIN BEVACIZUMAB Search
Food and Drug Administration's (FDA) Dermatologic and Ophthalmic Drug Advisory Committee's (DODAC) unanimous recommendation for approval of RAPTIVA® ...
http://www.bioportfolio.co.uk/AVASTIN+BEVACIZUMAB-bioweb.htm...

Wong's BioTech Stock Report - focus on the pipeline Fabrazyme ...
Genentech will co-promote Xolair and Raptiva with Xoma (NASDAQ: XOMA) and Novartis AG ... While the odds of marketing approval looks promising for Raptiva
, ...
http://www.bioportfolio.com/news/biotechsage_6.htm...

Psoriasis: Biologics hope to reach 8mill undiagnosed sufferers
The current leading biologics are Biogen Idec and Genentech's Amevive; Serono, Genentech and XOMA's Raptiva; Wyeth and Amgen's Enbrel and Johnson and ...
http://www.bioportfolio.com/news/datamonitor_115.htm...

BioPortfolio Limited Stakeholder Insight: Psoriasis - Biologics ...
Remicade and Raptiva are the clear favorites at third line 99 ... Raptiva's safety profile continues to signal doom for the brand 114 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_19.html...

The Dermatology Market Outlook to 2013: Competitive landscape ...
The market for psoriasis treatments is forecast to register strong growth between 2008-2013, driven by the performances of key drugs such as Raptiva, ...
http://www.bioportfolio.com/cgi-bin/acatalog/The-Dermatology...

BioPortfolio News: Reportlinker - Reportlinker Adds Monoclonal ...
5.2.4.1 Raptiva (efalizumab). 5.2.5 Asthma. 5.2.5.1 Xolair. 5.2.6 Age-Related Macular Degeneration ... Table 6.10 Global Sales of Raptiva 2003-2006 (US$mn)
...
http://www.bioportfolio.com/news/Reportlinker-Adds-Monoclona...

Results from other life science and pharmaceutical sites:

Genentech: Newsroom: Press Releases: News Release April 8, 2009
8 Apr 2009 ... April 8, 2009 -- Genentech, Inc. announced today a phased voluntary withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. ...
http://www.gene.com/gene/news/press-releases/display.do?meth...

FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. ...
8 Apr 2009 ... Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of ...
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc...

RAPTIVA USPI
been observed in patients treated with RAPTIVA (see WARNINGS and .... patients who resumed RAPTIVA treatment upon relapse of psoriasis, 31% (17/55) ...
http://www.gene.com/gene/products/information/pdf/raptiva-pr...

Raptiva (efalizumab) Feb 2009
[UPDATE 04/08/2009] Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva, a medication for treatment of ...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyA...

Genentech: Investors: Raptiva - Historical Sales
Skip to Content for Raptiva - Historical Sales Menu for Raptiva - Historical Sales About Us Menu Research Menu Development Menu Medicines Menu Investors ...
http://www.gene.com/gene/ir/financials/historical/raptiva.ht...

VOLUNTARY U.S. MARKET WITHDRAWAL OF RAPTIVA® (efalizumab)
8 Apr 2009 ... voluntary withdrawal of the psoriasis medication RAPTIVA ... clinical benefit from RAPTIVA, the balance between benefit and risk in the ...
http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformati...

Efalizumab - Wikipedia, the free encyclopedia
Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a medication designed to treat psoriasis. As its name implies, it is a recombinant humanized
...
http://en.wikipedia.org/wiki/Efalizumab...

Efalizumab (marketed as Raptiva) Information
21 Aug 2009 ... FDA has been informed by Genentech, Inc., the sponsor of Raptiva (efalizumab), of their decision to initiate a voluntary withdrawal of ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

Definition of Raptiva - NCI Dictionary of Cancer Terms
Raptiva binds to a molecule called LFA-1, and blocks the action of T cells (a type of white blood cell). It is a type of immunosuppressant. ...
http://www.nci.nih.gov/dictionary/?CdrID=589404...

FDA Approves Updated Labeling for Psoriasis Drug Raptiva
16 Oct 2008 ... The US Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening ...
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/20...

Google Custom Search

Search
  


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.